Get the Stockscreener App
15.15
5.78%
-0.93
After Hours:
16.08
0.93
+6.14%
Castle Biosciences Inc stock is traded at $15.15, with a volume of 455.55K.
It is down -5.78% in the last 24 hours and down -25.81% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
See More
Previous Close:
$16.08
Open:
$16
24h Volume:
455.55K
Relative Volume:
1.03
Market Cap:
$437.42M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-7.0465
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
-7.79%
1M Performance:
-25.81%
6M Performance:
-46.41%
1Y Performance:
-37.22%
1-Day Range:
$15.11
$16.20
1-Week Range:
$15.11
$16.66
52-Week Range:
$15.11
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
15.15 | 464.27M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
467.68 | 180.17B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
197.16 | 146.07B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
534.31 | 46.01B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.81 | 33.53B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.86 | 32.56B | 15.50B | 1.33B | 2.16B | 7.34 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Published on: 2025-07-30 02:23:31 - metal.it
The True Test of Success - thebossmagazine.com
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Healthcare Innovator Castle Biosciences Reveals Latest Growth Strategy at Major Investment Conference - Stock Titan
What Technical Tools Say About Castle Biosciences Inc. RecoveryConsistent Income Focused Trade List Analyzed - metal.it
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline - Yahoo Finance
When is Castle Biosciences Inc. stock expected to show significant growthFree Stock Insights For Every Investor - jammulinksnews.com
What is the dividend policy of Castle Biosciences Inc. stockExponential wealth increase - jammulinksnews.com
What are Castle Biosciences Inc. company’s key revenue driversInvest in stocks with strong fundamentals - jammulinksnews.com
How does Castle Biosciences Inc. generate profit in a changing economyBuild a portfolio that withstands market volatility - jammulinksnews.com
How volatile is Castle Biosciences Inc. stock compared to the marketRecord-breaking capital gains - jammulinksnews.com
What is the risk reward ratio of investing in Castle Biosciences Inc. stockHigh-yield portfolio picks - jammulinksnews.com
Should I hold or sell Castle Biosciences Inc. stock in 2025Capitalize on emerging trends for profits - jammulinksnews.com
Castle Biosciences (NASDAQ:CSTL) shareholders have endured a 58% loss from investing in the stock five years ago - Yahoo Finance
Is Castle Biosciences Inc. Stock Overbought or Oversold RSI Indicator AnalysisCapital Safe Smart Trades - Newser
Castle Biosciences Inc. Stock Performance After Earnings: Historical InsightsTop Gaining Low Risk Assets - Newser
Cerity Partners LLC Buys Shares of 21,138 Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences’ Founder, President and CEO Derek - GlobeNewswire
Castle Biosciences stock jumps after FDA grants Breakthrough Device status to melanoma test - MSN
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal - Santé log
Why Castle Biosciences Inc. stock is on top investor watchlistsSkyrocketing returns - jammulinksnews.com
Castle Biosciences' Founder, President and CEO Derek Maetzold Na - News Channel Nebraska Southeast
Castle Biosciences Inc. Stock Analysis and ForecastRapid profit acceleration - PrintWeekIndia
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - MSN
Leerink Partnrs Has Pessimistic View of CSTL Q2 Earnings - Defense World
Castle Biosciences stock jumps after FDA grants Breakthrough Device status - Investing.com
What drives Castle Biosciences Inc. stock priceRapidly expanding wealth - Autocar Professional
What analysts say about Castle Biosciences Inc. stockSkyrocketing investment returns - Autocar Professional
Castle Biosciences stock jumps after FDA grants Breakthrough Device status By Investing.com - Investing.com India
FDA Grants Breakthrough Status to Melanoma Test - Conexiant
FDA grants breakthrough device status to Castle Biosciences’ melanoma test - Investing.com
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test - GlobeNewswire
FDA Breakthrough: Castle Biosciences' New Melanoma Test Could Transform Cancer Diagnosis - Stock Titan
New York State Common Retirement Fund Has $3.27 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Is Castle Biosciences Inc. a good long term investmentHigh-margin investment plays - jammulinksnews.com
Teacher Retirement System of Texas Grows Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Stephens Inc. AR Has $273,000 Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):